A History of Modern Italy: Transformation and Continuity, 1796 to the Present

A History of Modern Italy addresses the question of how Italy\u27s modern history--from its prolonged process of nation-building in the nineteenth century to the crises of the last two decades--has produced a paradoxical blend of hyper-modernity and traditionalism that sets the country apart in the broader context of Western Europe. Author Anthony L. Cardoza explores how Italians have experienced seismic shifts in their social and economic landscape over the past two centuries, while simultaneously maintaining older cultural norms, social practices, and political methods. The book\u27s narrative of modern Italy incorporates and blends the research findings and methodological insights of the new quantitative and cultural historical scholarship of the past twenty-five years. In doing so, the book chronicles the regime changes that have taken the country from a liberal monarchy, through a fascist dictatorship, to a democratic republic while also delving into the economic and social history of the nation through these periods.https://ecommons.luc.edu/facultybooks/1167/thumbnail.jp

Anciennes et nouvelles aristocraties

Sans rien ignorer des spécificités de différentes aristocraties, anciennes et nouvelles, et des groupes qui les constituent, les auteurs de cet ouvrage tentent plutôt de les confronter, de rechercher les caractères communs qui les soudent, les différences qui les séparent et, plus encore, les fondements de clivages souvent ambigus entre aristocrates et non-aristocrates. Leur ambition est tout à la fois de présenter des études de cas précises réalisées en France, Grande-Bretagne, Allemagne, Italie, Hongrie, Finlande et Suède, un état des lieux ainsi que des recherches sur les noblesses menées par historiens, anthropologues et sociologues et enfin de proposer une analyse critique et comparative des évolutions de ces noblesses. Quel est le poids du symbolique mais aussi des décrochements politiques dans les transformations: disparition, désagrégation et parfois recomposition des anciennes aristocraties et constitution de nouvelles aristocraties ? Comment appréhender le phénomène aristocratique dans son extension européenne ? Comment articuler étude des tensions entre appartenances contradictoires - nationale et européenne, nobiliaire et démocratique - dans lesquelles sont parfois enserrés les aristocrates, et analyse des modes de reproduction de ces groupes ? Ce sont quelques-unes des questions majeures abordées dans ce livre

Edoxaban versus warfarin in patients with atrial fibrillation

Contains fulltext : 125374.pdf (publisher's version ) (Open Access)BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known. METHODS: We conducted a randomized, double-blind, double-dummy trial comparing two once-daily regimens of edoxaban with warfarin in 21,105 patients with moderate-to-high-risk atrial fibrillation (median follow-up, 2.8 years). The primary efficacy end point was stroke or systemic embolism. Each edoxaban regimen was tested for noninferiority to warfarin during the treatment period. The principal safety end point was major bleeding. RESULTS: The annualized rate of the primary end point during treatment was 1.50% with warfarin (median time in the therapeutic range, 68.4%), as compared with 1.18% with high-dose edoxaban (hazard ratio, 0.79; 97.5% confidence interval [CI], 0.63 to 0.99; P<0.001 for noninferiority) and 1.61% with low-dose edoxaban (hazard ratio, 1.07; 97.5% CI, 0.87 to 1.31; P=0.005 for noninferiority). In the intention-to-treat analysis, there was a trend favoring high-dose edoxaban versus warfarin (hazard ratio, 0.87; 97.5% CI, 0.73 to 1.04; P=0.08) and an unfavorable trend with low-dose edoxaban versus warfarin (hazard ratio, 1.13; 97.5% CI, 0.96 to 1.34; P=0.10). The annualized rate of major bleeding was 3.43% with warfarin versus 2.75% with high-dose edoxaban (hazard ratio, 0.80; 95% CI, 0.71 to 0.91; P<0.001) and 1.61% with low-dose edoxaban (hazard ratio, 0.47; 95% CI, 0.41 to 0.55; P<0.001). The corresponding annualized rates of death from cardiovascular causes were 3.17% versus 2.74% (hazard ratio, 0.86; 95% CI, 0.77 to 0.97; P=0.01), and 2.71% (hazard ratio, 0.85; 95% CI, 0.76 to 0.96; P=0.008), and the corresponding rates of the key secondary end point (a composite of stroke, systemic embolism, or death from cardiovascular causes) were 4.43% versus 3.85% (hazard ratio, 0.87; 95% CI, 0.78 to 0.96; P=0.005), and 4.23% (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.32). CONCLUSIONS: Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes. (Funded by Daiichi Sankyo Pharma Development; ENGAGE AF-TIMI 48 ClinicalTrials.gov number, NCT00781391.)